Crohn's Disease
820
72
96
469
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
199 trials with published results (24%)
Research Maturity
469 completed trials (57% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
13.8%
113 terminated out of 820 trials
80.6%
-5.9% vs benchmark
26%
214 trials in Phase 3/4
42%
199 of 469 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 469 completed trials
Clinical Trials (820)
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
Enabling Microbiomics- Driven Personalized Nutrition
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
Repetitive Transcranial Magnetic Stimulation Combined With Anti-inflammatory Diet in Crohn's Disease
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)
A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight